Rotonya M. Carr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rotonya M. Carr has a total of 325 co-authors. Here are the top co-authors by number of shared publications:
Eleonora Scorletti
Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA
7 shared publicationsAmanke Oranu
University of Pennsylvania, United States
5 shared publicationsChelsea Lin
Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA
5 shared publicationsRoyce Hooks
Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA
5 shared publications- Sookyoung Jeon
Department of Food and Nutrition, Kookmin University
5 shared publications Yedidya Saiman
Department of Medicine, Section of Hepatology, Lewis Katz School of Medicine Temple University, Philadelphia, PA, USA
4 shared publications
Latest Publications
- Open Access
- 20 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (8) , eadz2299
3D reconstruction of human liver tissue at cellular resolution
The liver contains an intricate microstructure that is critical for proper liver function. Architectural disruption of this spatial structure is pathologic. Unfortunately, two-dimensional (2D) histopathology—the gold standard for pathological understanding of many liver diseases—can misrepresent or leave gaps in our understanding of complex 3D structural features. Here, we used immunostaining, tissue clearing, microscopy, and computational software to create 3D multilobular reconstructions of both nonfibrotic and cirrhotic human liver tissue. We found that spatial architecture in human cirrhotic liver samples with varying etiologies had sinusoid zonal dysregulation, reduction in glutamine synthetase–expressing pericentral hepatocytes, regression of central vein networks, disruption of hepatic arterial networks, and fragmentation of biliary networks, which together suggest a pro-portalization/decentralization phenotype in cirrhotic tissue. Further implementation of 3D pathological analyses may provide a deeper understanding of cirrhotic pathobiology and inspire treatments for liver disease.
- 20 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (8) , eadz2299
Open Access3D reconstruction of human liver tissue at cellular resolution
The liver contains an intricate microstructure that is critical for proper liver function. Architectural disruption of this spatial structure is pathologic. Unfortunately, two-dimensional (2D) histopathology—the gold standard for pathological understanding of many liver diseases—can misrepresent or leave gaps in our understanding of complex 3D structural features. Here, we used immunostaining, tissue clearing, microscopy, and computational software to create 3D multilobular reconstructions of both nonfibrotic and cirrhotic human liver tissue. We found that spatial architecture in human cirrhotic liver samples with varying etiologies had sinusoid zonal dysregulation, reduction in glutamine synthetase–expressing pericentral hepatocytes, regression of central vein networks, disruption of hepatic arterial networks, and fragmentation of biliary networks, which together suggest a pro-portalization/decentralization phenotype in cirrhotic tissue. Further implementation of 3D pathological analyses may provide a deeper understanding of cirrhotic pathobiology and inspire treatments for liver disease.
- Open Access
- 1 December 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (12)
Development of an AI algorithm for early identification of MASLD in the electronic health record
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) affects ~30% of the US adult population, and its prevalence is increasing. Early-stage disease is often missed by clinicians as it is largely asymptomatic until cirrhosis develops. Recent advances in artificial intelligence (AI) have allowed for expanded electronic health record (EHR) identification of several diseases. We aimed to develop an algorithm that utilizes AI to identify patients with MASLD via a large-scale review within the EHR. Methods: We created a natural language processing (NLP) algorithm that identifies patients with hepatic steatosis on abdominal imaging and selects for patients meeting MASLD criteria. Validation was carried out via manual review of monthly generated cohorts. The algorithm was then utilized to retrieve a MASLD cohort for initial analysis. Demographics were summarized, and additional variables pertaining to early MASLD management were analyzed. Results: Our algorithm identified patients with MASLD with a positive predictive value (PPV) of over 93%. The NLP component of the algorithm identified hepatic steatosis in imaging reports with a PPV of up to 99.4% and excluded patients with alcohol use with a negative predictive value of ~95%. From a cohort spanning 6 months, 957 individuals with MASLD were identified by the algorithm, of which 14.6% (n=140) had a MASLD-related diagnosis code. Conclusions: We developed an AI algorithm that can perform a large-scale review of electronic health records to identify patients with MASLD with >93% accuracy. Our initial analysis suggests that a substantial proportion of individuals meeting MASLD criteria do not yet carry a MASLD-related diagnosis. Our work can be adapted by other institutions to enhance the detection of MASLD and alcohol use patterns, allowing for targeted interventions to prevent disease progression and improve outcomes.
- 1 December 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (12)
Open AccessDevelopment of an AI algorithm for early identification of MASLD in the electronic health record
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) affects ~30% of the US adult population, and its prevalence is increasing. Early-stage disease is often missed by clinicians as it is largely asymptomatic until cirrhosis develops. Recent advances in artificial intelligence (AI) have allowed for expanded electronic health record (EHR) identification of several diseases. We aimed to develop an algorithm that utilizes AI to identify patients with MASLD via a large-scale review within the EHR. Methods: We created a natural language processing (NLP) algorithm that identifies patients with hepatic steatosis on abdominal imaging and selects for patients meeting MASLD criteria. Validation was carried out via manual review of monthly generated cohorts. The algorithm was then utilized to retrieve a MASLD cohort for initial analysis. Demographics were summarized, and additional variables pertaining to early MASLD management were analyzed. Results: Our algorithm identified patients with MASLD with a positive predictive value (PPV) of over 93%. The NLP component of the algorithm identified hepatic steatosis in imaging reports with a PPV of up to 99.4% and excluded patients with alcohol use with a negative predictive value of ~95%. From a cohort spanning 6 months, 957 individuals with MASLD were identified by the algorithm, of which 14.6% (n=140) had a MASLD-related diagnosis code. Conclusions: We developed an AI algorithm that can perform a large-scale review of electronic health records to identify patients with MASLD with >93% accuracy. Our initial analysis suggests that a substantial proportion of individuals meeting MASLD criteria do not yet carry a MASLD-related diagnosis. Our work can be adapted by other institutions to enhance the detection of MASLD and alcohol use patterns, allowing for targeted interventions to prevent disease progression and improve outcomes.
- Top Cited Papers
- 7 November 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (5) , 1326-1340
Semaglutide therapy for metabolic dysfunction–associated steatohepatitis: November 2025 updates to AASLD Practice Guidance
This practice recommendation serves as an update to the 2023 AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction–associated steatotic liver disease (MASLD), and provides implementable guidance on patient selection for treatment, consideration of comorbidities, and monitoring of treatment safety and efficacy of semaglutide. FDA-indication and Practice Recommendation: The Wegovy formulation, whose main ingredient is semaglutide, received accelerated FDA approval in August 2025 for treating MASH with moderate-to-advanced fibrosis (consistent with stages F2–F3 fibrosis), based on interim results of the phase 3 ESSENCE trial where 72 weeks of 2.4 mg/week subcutaneous injection resulted in achievement of both primary histologic endpoints: (1) resolution of MASH without worsening of fibrosis (62.9% vs. 34.3% placebo, p p Patient Selection: Candidates should have MASH with stage 2–3 fibrosis, identified using non-invasive tests (NITs) such as VCTE (8–15 kPa), MRE (3.1–4.4 kPa), or ELF (9.2–10.5), rather than liver biopsy, which is impractical and unnecessary for most patients. In those with VCTE (15–20 kPa), MRE (4.4–5 kPa), or ELF (10.5–11.3), an individualized decision to treat should be based on exclusion of cirrhosis with another confirmatory NIT, or cross-sectional imaging excluding nodular-appearing liver contour and signs of portal hypertension, or a platelet count of 20 kPa, MRE>5.0 kPa, ELF>11.3, and/or evidence of portal hypertension), those with compensated cirrhosis who are receiving semaglutide for another FDA-approved indication should be monitored carefully. Monitoring and Safety: Semaglutide showed a favorable hepatic safety profile in the ESSENCE trial, with no discontinuations due to liver enzyme elevations. Routine hepatic panels are recommended only as clinically indicated. The most common adverse events were gastrointestinal (nausea, diarrhea, constipation, vomiting), generally mild and transient; patient education and dose titration help improve tolerance. Clinicians should monitor for rare but serious risks, including acute kidney injury (from dehydration), symptomatic gallbladder disease, pancreatitis, thyroid C-cell tumors, retinopathy progression, and lean mass loss. Treatment Response and Concomitant Therapy: Lifestyle modification remains the cornerstone of MASLD/MASH management alongside semaglutide. Combination use of resmetirom with semaglutide 2.4mg/week has not been studied. While no NITs reliably predict histologic response at the individual patient level, reductions from baseline to 72 weeks of treatment suggest significant improvement in MASH resolution (ALT ≥17 U/L or ≥20%) and fibrosis improvement (VCTE LSM ≥30%; MRE LSM ≥20%; ELF ≥0.5). Non-response may be suspected if ALT or NITs worsen. The benefit is uncertain if a suboptimal response occurs, and may require an individualized approach and further follow-up.
- 7 November 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (5) , 1326-1340
Top Cited PapersSemaglutide therapy for metabolic dysfunction–associated steatohepatitis: November 2025 updates to AASLD Practice Guidance
This practice recommendation serves as an update to the 2023 AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction–associated steatotic liver disease (MASLD), and provides implementable guidance on patient selection for treatment, consideration of comorbidities, and monitoring of treatment safety and efficacy of semaglutide. FDA-indication and Practice Recommendation: The Wegovy formulation, whose main ingredient is semaglutide, received accelerated FDA approval in August 2025 for treating MASH with moderate-to-advanced fibrosis (consistent with stages F2–F3 fibrosis), based on interim results of the phase 3 ESSENCE trial where 72 weeks of 2.4 mg/week subcutaneous injection resulted in achievement of both primary histologic endpoints: (1) resolution of MASH without worsening of fibrosis (62.9% vs. 34.3% placebo, p p Patient Selection: Candidates should have MASH with stage 2–3 fibrosis, identified using non-invasive tests (NITs) such as VCTE (8–15 kPa), MRE (3.1–4.4 kPa), or ELF (9.2–10.5), rather than liver biopsy, which is impractical and unnecessary for most patients. In those with VCTE (15–20 kPa), MRE (4.4–5 kPa), or ELF (10.5–11.3), an individualized decision to treat should be based on exclusion of cirrhosis with another confirmatory NIT, or cross-sectional imaging excluding nodular-appearing liver contour and signs of portal hypertension, or a platelet count of 20 kPa, MRE>5.0 kPa, ELF>11.3, and/or evidence of portal hypertension), those with compensated cirrhosis who are receiving semaglutide for another FDA-approved indication should be monitored carefully. Monitoring and Safety: Semaglutide showed a favorable hepatic safety profile in the ESSENCE trial, with no discontinuations due to liver enzyme elevations. Routine hepatic panels are recommended only as clinically indicated. The most common adverse events were gastrointestinal (nausea, diarrhea, constipation, vomiting), generally mild and transient; patient education and dose titration help improve tolerance. Clinicians should monitor for rare but serious risks, including acute kidney injury (from dehydration), symptomatic gallbladder disease, pancreatitis, thyroid C-cell tumors, retinopathy progression, and lean mass loss. Treatment Response and Concomitant Therapy: Lifestyle modification remains the cornerstone of MASLD/MASH management alongside semaglutide. Combination use of resmetirom with semaglutide 2.4mg/week has not been studied. While no NITs reliably predict histologic response at the individual patient level, reductions from baseline to 72 weeks of treatment suggest significant improvement in MASH resolution (ALT ≥17 U/L or ≥20%) and fibrosis improvement (VCTE LSM ≥30%; MRE LSM ≥20%; ELF ≥0.5). Non-response may be suspected if ALT or NITs worsen. The benefit is uncertain if a suboptimal response occurs, and may require an individualized approach and further follow-up.
- Top Cited PapersOpen Access
- 11 February 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (7)
Metabolic dysfunction–associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a major cause of liver disease worldwide, and our understanding of its pathogenesis continues to evolve. MASLD progresses from steatosis to steatohepatitis, fibrosis, and cirrhosis, and this Review explores how the gut microbiome and their metabolites contribute to MASLD pathogenesis. We explore the complexity and importance of the intestinal barrier function and how disruptions of the intestinal barrier and dysbiosis work in concert to promote the onset and progression of MASLD. The Review focuses on specific bacterial, viral, and fungal communities that impact the trajectory of MASLD and how specific metabolites (including ethanol, bile acids, short chain fatty acids, and other metabolites) contribute to disease pathogenesis. Finally, we underscore how knowledge of the interaction between gut microbes and the intestinal barrier may be leveraged for MASLD microbial-based therapeutics. Here, we include a discussion of the therapeutic potential of prebiotics, probiotics, postbiotics, and microbial-derived metabolites.
- 11 February 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (7)
Top Cited PapersOpen AccessMetabolic dysfunction–associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a major cause of liver disease worldwide, and our understanding of its pathogenesis continues to evolve. MASLD progresses from steatosis to steatohepatitis, fibrosis, and cirrhosis, and this Review explores how the gut microbiome and their metabolites contribute to MASLD pathogenesis. We explore the complexity and importance of the intestinal barrier function and how disruptions of the intestinal barrier and dysbiosis work in concert to promote the onset and progression of MASLD. The Review focuses on specific bacterial, viral, and fungal communities that impact the trajectory of MASLD and how specific metabolites (including ethanol, bile acids, short chain fatty acids, and other metabolites) contribute to disease pathogenesis. Finally, we underscore how knowledge of the interaction between gut microbes and the intestinal barrier may be leveraged for MASLD microbial-based therapeutics. Here, we include a discussion of the therapeutic potential of prebiotics, probiotics, postbiotics, and microbial-derived metabolites.
- Open Access
LiverMap pipeline for 3D imaging of human liver reveals volumetric spatial dysregulation of cirrhotic vasculobiliary architecture
The liver contains an intricate microstructure that is critical for liver function. Architectural disruption of this spatial structure is pathologic. Unfortunately, 2D histopathology – the gold standard for pathological understanding of many liver diseases – can misrepresent or leave gaps in our understanding of complex 3D structural features. Here, we utilized immunostaining, tissue clearing, microscopy, and computational software to create 3D multilobular reconstructions of both non-fibrotic and cirrhotic human liver tissue. We found that spatial architecture in human cirrhotic liver samples with varying etiologies had sinusoid zonation dysregulation, reduction in glutamine synthetase-expressing pericentral hepatocytes, regression of central vein networks, disruption of hepatic arterial networks, and fragmentation of biliary networks, which together suggest a pro-portalization/decentralization phenotype in cirrhotic tissue. Further implementation of 3D pathological analyses may provide a deeper understanding of cirrhotic pathobiology and inspire novel treatments for liver disease.
Open AccessLiverMap pipeline for 3D imaging of human liver reveals volumetric spatial dysregulation of cirrhotic vasculobiliary architecture
The liver contains an intricate microstructure that is critical for liver function. Architectural disruption of this spatial structure is pathologic. Unfortunately, 2D histopathology – the gold standard for pathological understanding of many liver diseases – can misrepresent or leave gaps in our understanding of complex 3D structural features. Here, we utilized immunostaining, tissue clearing, microscopy, and computational software to create 3D multilobular reconstructions of both non-fibrotic and cirrhotic human liver tissue. We found that spatial architecture in human cirrhotic liver samples with varying etiologies had sinusoid zonation dysregulation, reduction in glutamine synthetase-expressing pericentral hepatocytes, regression of central vein networks, disruption of hepatic arterial networks, and fragmentation of biliary networks, which together suggest a pro-portalization/decentralization phenotype in cirrhotic tissue. Further implementation of 3D pathological analyses may provide a deeper understanding of cirrhotic pathobiology and inspire novel treatments for liver disease.
- Open Access
- 1 May 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (5)
Pragmatic strategies to address health disparities along the continuum of care in chronic liver disease
Racial, ethnic, and socioeconomic disparities exist in the prevalence and natural history of chronic liver disease, access to care, and clinical outcomes. Solutions to improve health equity range widely, from digital health tools to policy changes. The current review outlines the disparities along the chronic liver disease health care continuum from screening and diagnosis to the management of cirrhosis and considerations of pre-liver and post-liver transplantation. Using a health equity research and implementation science framework, we offer pragmatic strategies to address barriers to implementing high-quality equitable care for patients with chronic liver disease.
- 1 May 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (5)
Open AccessPragmatic strategies to address health disparities along the continuum of care in chronic liver disease
Racial, ethnic, and socioeconomic disparities exist in the prevalence and natural history of chronic liver disease, access to care, and clinical outcomes. Solutions to improve health equity range widely, from digital health tools to policy changes. The current review outlines the disparities along the chronic liver disease health care continuum from screening and diagnosis to the management of cirrhosis and considerations of pre-liver and post-liver transplantation. Using a health equity research and implementation science framework, we offer pragmatic strategies to address barriers to implementing high-quality equitable care for patients with chronic liver disease.
- 5 October 2023
- Published by Georg Thieme Verlag KG in Seminars in Liver Disease
- Vol. 43 (04) , 367-382
Mechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases
The steatotic diseases of metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and chronic hepatitis C (HCV) account for the majority of liver disease prevalence, morbidity, and mortality worldwide. While these diseases have distinct pathogenic and clinical features, dysregulated lipid droplet (LD) organelle biology represents a convergence of pathogenesis in all three. With increasing understanding of hepatocyte LD biology, we now understand the roles of LD proteins involved in these diseases but also how genetics modulate LD biology to either exacerbate or protect against the phenotypes associated with steatotic liver diseases. Here, we review the history of the LD organelle and its biogenesis and catabolism. We also review how this organelle is critical not only for the steatotic phenotype of liver diseases but also for their advanced phenotypes. Finally, we summarize the latest attempts and challenges of leveraging LD biology for therapeutic gain in steatotic diseases. In conclusion, the study of dysregulated LD biology may lead to novel therapeutics for the prevention of disease progression in the highly prevalent steatotic liver diseases of MASLD, ALD, and HCV.
- 5 October 2023
- Published by Georg Thieme Verlag KG in Seminars in Liver Disease
- Vol. 43 (04) , 367-382
Mechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases
The steatotic diseases of metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and chronic hepatitis C (HCV) account for the majority of liver disease prevalence, morbidity, and mortality worldwide. While these diseases have distinct pathogenic and clinical features, dysregulated lipid droplet (LD) organelle biology represents a convergence of pathogenesis in all three. With increasing understanding of hepatocyte LD biology, we now understand the roles of LD proteins involved in these diseases but also how genetics modulate LD biology to either exacerbate or protect against the phenotypes associated with steatotic liver diseases. Here, we review the history of the LD organelle and its biogenesis and catabolism. We also review how this organelle is critical not only for the steatotic phenotype of liver diseases but also for their advanced phenotypes. Finally, we summarize the latest attempts and challenges of leveraging LD biology for therapeutic gain in steatotic diseases. In conclusion, the study of dysregulated LD biology may lead to novel therapeutics for the prevention of disease progression in the highly prevalent steatotic liver diseases of MASLD, ALD, and HCV.
- Open Access
- 27 September 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (10)
Embracing the principles of practice transfer to get the word out on the new metabolic dysfunction-associated steatotic liver disease nomenclature
- 27 September 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (10)
Open AccessEmbracing the principles of practice transfer to get the word out on the new metabolic dysfunction-associated steatotic liver disease nomenclature
- Open Access
- 13 September 2023
- Published by Elsevier in Molecular Metabolism
- Vol. 78, 101804
Ceramide synthase 6 (CerS6) is upregulated in alcohol-associated liver disease and exhibits sex-based differences in the regulation of energy homeostasis and lipid droplet accumulation
- 13 September 2023
- Published by Elsevier in Molecular Metabolism
- Vol. 78, 101804
Open AccessCeramide synthase 6 (CerS6) is upregulated in alcohol-associated liver disease and exhibits sex-based differences in the regulation of energy homeostasis and lipid droplet accumulation
- Open Access
- 9 August 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 62, 102149
Large-scale identification of undiagnosed hepatic steatosis using natural language processing
- 9 August 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 62, 102149
Open AccessLarge-scale identification of undiagnosed hepatic steatosis using natural language processing